Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indinavir + Ritonavir + d4T + 3TC in HIV
NCT00002241Phase 2Unknown
- Sponsor
- Merck & Co.
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of indinavir in human immunodeficiency virus infection (HIV), sponsored by Merck & Co. Primary endpoints: Proportion of patients with plasma viral RNA below 400 copies/ml at 24 weeks and Safety and tolerability at 24 weeks. Status: unknown.
02
Drugs
indinavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00002241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002241.